{"id":25796,"date":"2025-05-27T19:42:36","date_gmt":"2025-05-27T14:12:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25796"},"modified":"2025-09-26T11:15:20","modified_gmt":"2025-09-26T05:45:20","slug":"dermatomyositis-treatment-outlook","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook","title":{"rendered":"Unraveling the Complexities of Dermatomyositis Treatment: A Comprehensive Review and Future Perspectives"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0bd45d7e65e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0bd45d7e65e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Understanding_the_Disease\" >Understanding the Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Current_Diagnostic_and_Dermatomyositis_Treatment_Landscape\" >Current Diagnostic and Dermatomyositis Treatment Landscape&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Ongoing_Challenges_and_Unresolved_Obstacles_in_Dermatomyositis_Treatment\" >Ongoing Challenges and Unresolved Obstacles in Dermatomyositis Treatment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Heterogeneity_in_the_Pathophysiology\" >Heterogeneity in the Pathophysiology&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Complexity_in_Epidemiological_Data\" >Complexity in Epidemiological Data&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Early_Detection_and_Diagnostic_Gaps\" >Early Detection and Diagnostic Gaps&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Scarcity_of_Effective_Therapies\" >Scarcity of Effective Therapies&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Challenges_in_the_Animal_Model\" >Challenges in the Animal Model&nbsp;&nbsp;<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Promising_Triumphs_on_the_Horizon_for_Dermatomyositis_Treatment\" >Promising Triumphs on the Horizon for Dermatomyositis Treatment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#Brepocitinib_Tyrosine_kinase_TYK2_and_Janus_kinases1_JAK1_inhibitor\" >Brepocitinib: Tyrosine kinase (TYK2) and Janus kinases1 (JAK1) inhibitor<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\/#PF-06823859_Interferon_beta_one_fibroblast_IFN%CE%B21_blocker\" >PF-06823859: Interferon beta one fibroblast (IFN\u03b21) blocker<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p>Dermatomyositis, characterized by muscle weakness and skin symptoms, is a condition linked to increased morbidity and mortality. It markedly affects the quality of life for individuals afflicted, as well as the well-being of their families. According to DelveInsight\u2019s estimates, in <strong>2023<\/strong>, there were <strong>nearly 72K <\/strong>diagnosed <a href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-epidemiology-forecast\">prevalent cases of dermatomyositis<\/a> in the seven major markets (the US, Germany, France, Italy, Spain, the UK, and Japan), with approximately <strong>91% of cases<\/strong> occurring in adults and <strong>9% in juveniles.&nbsp;<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-understanding-the-disease\"><span class=\"ez-toc-section\" id=\"Understanding_the_Disease\"><\/span><strong>Understanding the Disease<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Dermatomyositis is a rare autoimmune disorder associated with muscle inflammation (myositis) and skin inflammation (dermatitis). It falls under the classification of idiopathic inflammatory myopathies (IIM), a group comprising various connective tissue disorders characterized by the progressive weakening of muscles. The signs and symptoms of dermatomyositis may manifest suddenly or evolve gradually over time. The most <a href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market\">common dermatomyositis symptoms<\/a> include skin rash, muscle pain and weakness, fatigue, and ulcers. The precise cause of dermatomyositis remains unknown, although it is believed to stem from a combination of genetic predisposition and environmental stimuli.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/dermatomyositis-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152656\/Dermatomyositis-infographic-1024x194.webp\" alt=\"Dermatomyositis infographic\" class=\"wp-image-25804\" style=\"aspect-ratio:5.260273972602739;width:840px;height:auto\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152656\/Dermatomyositis-infographic-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152656\/Dermatomyositis-infographic-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152656\/Dermatomyositis-infographic-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152656\/Dermatomyositis-infographic-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152656\/Dermatomyositis-infographic-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152656\/Dermatomyositis-infographic-1568x297.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152656\/Dermatomyositis-infographic.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Dermatomyositis affects people of all ages and genders, but is more common among women. The disease can occur in childhood and is usually referred to as juvenile dermatomyositis (JDM). While both adult and juvenile dermatomyositis conditions exhibit characteristic signs like distinctive skin rashes and muscle inflammation, they are heterogeneous with various additional features and complications. For example, vasculopathy is more prevalent in juvenile cases than adult dermatomyositis. Similarly, although children face an elevated risk of calcinosis and ulceration, their long-term outlook is generally more favorable.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"864\" height=\"218\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152432\/Major-Symptoms-of-Dermatomyositis.png\" alt=\"Major Symptoms of Dermatomyositis\" class=\"wp-image-25801\" style=\"aspect-ratio:3.951219512195122;width:839px;height:auto\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152432\/Major-Symptoms-of-Dermatomyositis.png 864w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152432\/Major-Symptoms-of-Dermatomyositis-300x76.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152432\/Major-Symptoms-of-Dermatomyositis-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152432\/Major-Symptoms-of-Dermatomyositis-768x194.png 768w\" sizes=\"(max-width: 864px) 100vw, 864px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-diagnostic-and-dermatomyositis-treatment-landscape-nbsp\"><span class=\"ez-toc-section\" id=\"Current_Diagnostic_and_Dermatomyositis_Treatment_Landscape\"><\/span><strong>Current Diagnostic and Dermatomyositis Treatment Landscape&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Identifying the disease poses a challenge because of its resemblance in presentation to other forms of myositis. Accurate diagnosis involves a blend of clinical assessment, identification of distinctive physical indicators, specific laboratory tests, imaging examinations, and, in certain instances, muscle biopsies. Diagnostic criteria have been formulated, taking into account classification, pathological features, and symptoms of the disease.<\/p>\n\n\n\n<p>In 1975, Bohan and Peter first suggested a set of five criteria to aid in the diagnosis and classification of dermatomyositis, which was accepted worldwide. Later on, other diagnostic criteria, including the European League Against Rheumatism\/American College of Rheumatology (EULAR\/ACR) guideline for adults and juvenile IIM, published in 2017, emerged.&nbsp;<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-f9273bb7-7fff-65e6-1b83-adeea1f8792b\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"center\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"141\" \/><col width=\"255\" \/><col width=\"218\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 9.45pt;\">\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\" colspan=\"3\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: center; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Comparing Juvenile and Adult Dermatomyositis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 8.95pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Characteristic<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Juvenile Dermatomyositis<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Adult Dermatomyositis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 8.5pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">The peak age of onset<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">7&nbsp;years<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">30&ndash;50&nbsp;years<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 8.5pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Proximal weakness<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">85&ndash;95%<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">88%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 18pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Rash<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Maybe atypical, generalized, more frequent ulcerative changes<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Typical heliotrope rash, Gottron&rsquo;s papules<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 8.5pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Malignancy<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">1%<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">15&ndash;24%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 17.5pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Muscle enzyme<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">A slight elevation is seen; proximity to normal<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Elevated<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 17.5pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Amyopathic dermatomyositis<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Less common<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">More common<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 8.5pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Prognosis<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Better prognosis, if treated properly<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Poor prognosis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 18pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Interstitial lung disease<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Less common<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">It affects 20&ndash;65% of adults; rapidly progressive\/chronic course<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 17.5pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Calcinosis or ulceration<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Extensive, poor response to therapy; 26&ndash;40%<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Less common appear late in the disease course; 2&ndash;16%<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 41.8pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Myositis-specific autoantibodies<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Seen in &gt;60% of children with myositis, Anti-p155\/140 is the most common autoantibody in JDM, with no association with malignancy<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Seen in 80% of adults with dermatomyositis, Anti-Jo1, and other antisynthetase autoantibodies are most common and strongly associated with malignancy<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 8.5pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Vasculopathy<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">More prominent<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 1.45pt 0pt 1.45pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 0.5pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Less common<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>There is no <a href=\"https:\/\/www.delveinsight.com\/blog\/inflammatory-myositis-treatment\">cure for dermatomyositis<\/a>, but medicines can minimize symptoms, reduce inflammation and vasculitis, and enhance the patient\u2019s quality of life. The goals of managing dermatomyositis are focused on treating muscle weakness and skin disease and addressing any other underlying complications, including cardiac, pulmonary, gastrointestinal, joint, and malignancies. The recent approval of <strong>OCTAGAM<\/strong> and several management guidelines, including the British Society for Rheumatology guideline, the Japanese Society of Rheumatology guideline, and others, have simplified the treatment landscape for dermatomyositis. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market\">first-line treatment for dermatomyositis<\/a> includes the use of <strong>systemic glucocorticoids<\/strong> with or without <strong>immunosuppressants<\/strong>. Other dermatomyositis medications, including <strong>antimalarial<\/strong> <strong>drugs<\/strong>, <strong>antibiotics<\/strong>, and <strong>topical ointments<\/strong>, are given individually or in combination to eliminate symptoms. Further, <strong>rituximab<\/strong>, <strong>mycophenolate<\/strong> <strong>mofetil<\/strong>, <strong>calcineurin inhibitors<\/strong>, <strong>IVIG<\/strong>, and <strong>cyclophosphamide<\/strong> are preferred for resistant cases, patients unresponsive to initial treatment.&nbsp;<\/p>\n\n\n\n<p>Medical therapy for skin disease includes topical and systemic medications. Topical agents include <strong>corticosteroids<\/strong> and <strong>calcineurin inhibitors<\/strong>. Most patients require systemic drugs to control skin disease, including <strong>hydroxychloroquine<\/strong> and <strong>methotrexate<\/strong>. Besides, nonpharmacological management options such as diet and physiotherapy, plasmapheresis, sun-protective measures, extracorporeal photochemotherapy, and total body irradiation, are employed as adjunctive treatment methods in cases of therapy-resistant dermatomyositis. While surgery is not a common approach for dermatomyositis, gastrotomy may be considered beneficial for patients experiencing severe esophageal dysfunction, and surgical removal of calcinotic nodules, if present, may also be performed.<\/p>\n\n\n\n<p>According to DelveInsight, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market\"><strong>market size for immunoglobulins<\/strong><\/a> in dermatomyositis was approximately <strong>USD 119 million<\/strong> in <strong>2023<\/strong>, making it the leading treatment segment ahead of biologics, immunosuppressants, and corticosteroids. The overall dermatomyositis market size in the 7MM reached around <strong>USD 187 million<\/strong> in <strong>2023 <\/strong>and is expected to grow at a <strong>CAGR of 16.8%,<\/strong> driven by increasing disease awareness, improved diagnostics, and the launch of emerging therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"282\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193656\/Current-Dermatomyositis-Treatment-Options-1024x282.png\" alt=\"Current Dermatomyositis Treatment Options\" class=\"wp-image-32311\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193656\/Current-Dermatomyositis-Treatment-Options-1024x282.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193656\/Current-Dermatomyositis-Treatment-Options-300x83.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193656\/Current-Dermatomyositis-Treatment-Options-150x41.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193656\/Current-Dermatomyositis-Treatment-Options-768x211.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193656\/Current-Dermatomyositis-Treatment-Options-1536x422.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193656\/Current-Dermatomyositis-Treatment-Options-2048x563.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ongoing-challenges-and-unresolved-obstacles-in-dermatomyositis-treatment\"><span class=\"ez-toc-section\" id=\"Ongoing_Challenges_and_Unresolved_Obstacles_in_Dermatomyositis_Treatment\"><\/span><strong>Ongoing Challenges and Unresolved Obstacles in Dermatomyositis Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>To ensure proper care and enhance the well-being of individuals diagnosed with dermatomyositis, it is essential to acknowledge and address various deficiencies to fill the gaps. Some hurdles and challenges in the development and appropriate management of dermatomyositis include: Ensuring optimal care and improving the well-being of individuals diagnosed with dermatomyositis requires addressing various gaps and overcoming dermatomyositis treatment challenges. Some hurdles include:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-heterogeneity-in-the-pathophysiology-nbsp\"><span class=\"ez-toc-section\" id=\"Heterogeneity_in_the_Pathophysiology\"><\/span><strong>Heterogeneity in the Pathophysiology&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Although adults and JDM share the hallmark features of dermatomyositis, they are heterogeneous disorders with various additional disease features and complications. The occurrence of significant clinical aspects like calcinosis, interstitial lung disease, and malignancy significantly differs between adult and juvenile cases. Consequently, comparing disease outcomes between juvenile and adult myositis is <strong>challenging due to the absence of standardized outcome measures.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-complexity-in-epidemiological-data-nbsp\"><span class=\"ez-toc-section\" id=\"Complexity_in_Epidemiological_Data\"><\/span><strong>Complexity in Epidemiological Data&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Dermatomyositis is rare, and its epidemiology studies on prevalence or occurrence are scarce. The complex pathophysiology of dermatomyositis, coupled with overlapping symptoms with other idiopathic inflammatory myopathies (IIMs), adds intricacy to its epidemiological study. There is a need for new studies to acquire a more comprehensive understanding of the disease epidemiology, encompassing its various types, degrees of severity, and variations across different geographical regions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-early-detection-and-diagnostic-gaps-nbsp\"><span class=\"ez-toc-section\" id=\"Early_Detection_and_Diagnostic_Gaps\"><\/span><strong>Early Detection and Diagnostic Gaps&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Early detection of dermatomyositis is crucial for initiating appropriate patient management. Myositis mimics are prevalent, and their shared features with idiopathic inflammatory myopathies (IIMs) present a diagnostic challenge, often leading to misdiagnosis and delays in dermatomyositis treatment. Such delays can result in complications such as lipodystrophy, loss of function and muscle mass, calcinosis, joint contractures, and involvement of extra-muscular tissues.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scarcity-of-effective-therapies-nbsp\"><span class=\"ez-toc-section\" id=\"Scarcity_of_Effective_Therapies\"><\/span><strong>Scarcity of Effective Therapies&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>OCTAGAM 10% is the only approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market\">drug for dermatomyositis treatment<\/a>. The use of OCTAGAM is restricted due to potential side effects such as flushing, headache, dizziness, chills, etc. Despite standard off-label therapies, patients frequently endure flares, leading to disability and reduced productivity. Additionally, these off-label medications, including corticosteroids, are linked to various side effects and adverse events, such as osteoporosis, heightened susceptibility to infections, cushingoid features, and more. There is a pressing <strong>need for safer and more effective treatment options<\/strong> to enhance patient outcomes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-challenges-in-the-animal-model-nbsp-nbsp\"><span class=\"ez-toc-section\" id=\"Challenges_in_the_Animal_Model\"><\/span><strong>Challenges in the Animal Model&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Animal models serve as crucial tools for exploring new agents and understanding the mechanisms of various diseases. Despite various animal models providing insights into the underlying mechanisms of idiopathic inflammatory myopathies (IIM), none of these models fully replicate the clinical and pathological characteristics of human IIM, specifically dermatomyositis, resulting in limited resemblance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-promising-triumphs-on-the-horizon-for-dermatomyositis-treatment\"><span class=\"ez-toc-section\" id=\"Promising_Triumphs_on_the_Horizon_for_Dermatomyositis_Treatment\"><\/span><strong>Promising Triumphs on the Horizon for Dermatomyositis Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In the last two decades, a substantial advancement in research has yielded new insights into the genetic risk factors and mechanisms underlying dermatomyositis, paving the way for promising therapeutic approaches to address the urgent need for effective dermatomyositis treatments.<\/p>\n\n\n\n<p>Several <a href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-pipeline-insight\"><strong>dermatomyositis therapies<\/strong><\/a> are progressing through late-stage clinical development, including <strong>Priovant Therapeutics\/Pfizer\u2019s Brepocitinib,<\/strong> <strong>Kezar Life Sciences\u2019 KZR-616 (zetomipzomib)<\/strong>, <strong>argenx\u2019s EFG PH20 (efgartigimod + PH20 hyaluronidase)<\/strong>, <strong>Pfizer\u2019s PF-06823859 (dazukibart)<\/strong>, <strong>CSL Behring\u2019s HIZENTRA<\/strong>, <strong>Horizon Therapeutics\u2019 Daxdilimab (HZN-7734)<\/strong>, and <strong>PAEAN Biotechnology\u2019s PN-101<\/strong>. These dermatomyositis therapies, many of which are already approved for other autoimmune conditions, are currently in Phase II\/III and Phase III trials. Their favorable safety profiles and demonstrated efficacy in related indications support their potential to significantly improve outcomes in dermatomyositis.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"344\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193920\/Emerging-Therapies-for-Dermatomyositis-1024x344.png\" alt=\"Emerging Therapies for Dermatomyositis\" class=\"wp-image-32312\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193920\/Emerging-Therapies-for-Dermatomyositis-1024x344.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193920\/Emerging-Therapies-for-Dermatomyositis-300x101.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193920\/Emerging-Therapies-for-Dermatomyositis-150x50.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193920\/Emerging-Therapies-for-Dermatomyositis-768x258.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193920\/Emerging-Therapies-for-Dermatomyositis-1536x516.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27193920\/Emerging-Therapies-for-Dermatomyositis-2048x689.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-brepocitinib-tyrosine-kinase-tyk2-and-janus-kinases1-jak1-inhibitor\"><span class=\"ez-toc-section\" id=\"Brepocitinib_Tyrosine_kinase_TYK2_and_Janus_kinases1_JAK1_inhibitor\"><\/span><strong>Brepocitinib: Tyrosine kinase (TYK2) and Janus kinases1 (JAK1) inhibitor<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Numerous case reports on tofacitinib in dermatomyositis provide compelling evidence supporting the potential efficacy of brepocitinib<\/li>\n\n\n\n<li>The pathobiology of dermatomyositis is influenced by dysregulation in cytokines, with signaling mediated by <strong>TYK2 and JAK1<\/strong>, particularly Type I interferon. This suggests that <strong>brepocitinib may exhibit greater efficacy than tofacitinib<\/strong><\/li>\n\n\n\n<li>Comparative analyses between brepocitinib (30 mg daily) and tofacitinib in various autoimmune conditions indicate that dosing brepocitinib at 30 mg daily could yield clinically meaningful efficacy in dermatomyositis<\/li>\n\n\n\n<li>Delveinsight analysts anticipate that the drug will enter the US market by 2026 and reach its peak in the seventh year<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pf-06823859-interferon-beta-one-fibroblast-ifn\u03b21-blocker\"><span class=\"ez-toc-section\" id=\"PF-06823859_Interferon_beta_one_fibroblast_IFN%CE%B21_blocker\"><\/span><strong>PF-06823859:<\/strong> <strong>Interferon beta one fibroblast (IFN\u03b21) blocker<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In the Phase I trial, PF-06823859 demonstrated an acceptable safety, tolerability, and PK profile that supports clinical development for treating disorders associated with increased interferon \u03b2 levels, such as dermatomyositis or systemic lupus erythematosus.<\/li>\n\n\n\n<li>In the Phase II trial, the drug improved clinical parameters like Manual Muscle Testing-8, Physician Global Assessment, patient-reported outcomes, and Health Assessment Questionnaire Disability Index in patients with muscle-predominant refractory moderate-to-severe dermatomyositis.<\/li>\n\n\n\n<li>As per Delveinsight, the drug is anticipated to enter EU4 (Germany, France, Italy, and Spain) and the UK market by 2027 and will attain its peak in the seventh year.&nbsp;<\/li>\n<\/ul>\n\n\n\n<p>In summary, dermatomyositis is a rare and complex condition marked by limited public awareness. Diagnosis poses challenges, often resulting in significant delays in obtaining a definitive <a href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-epidemiology-forecast\" class=\"ek-link\">diagnosis for dermatomyositis patients<\/a>. Additionally, existing biotherapies do not provide a cure. The visible skin manifestations, coupled with the complexities of the disease, may contribute to psychosocial and emotional stress in individuals with dermatomyositis. As a result, there is an urgent call for extensive research and development to tackle the existing challenges in managing dermatomyositis.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/dermatomyositis-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27194038\/Dermatomyositis-Market-Outlook-1024x194.png\" alt=\"Dermatomyositis Market Outlook\" class=\"wp-image-32313\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27194038\/Dermatomyositis-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27194038\/Dermatomyositis-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27194038\/Dermatomyositis-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27194038\/Dermatomyositis-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27194038\/Dermatomyositis-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/27194038\/Dermatomyositis-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Frequently Asked Questions<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1758865387381\"><strong class=\"schema-faq-question\"><strong>What is dermatomyositis and how common is it?<\/strong><\/strong> <p class=\"schema-faq-answer\">Dermatomyositis is a rare autoimmune disease characterized by inflammation of muscle (myositis) and skin (dermatitis). In 2023, there were approximately <strong>72,000 diagnosed cases<\/strong> in the seven major markets (US, Germany, France, Italy, Spain, UK, Japan). About <strong>91%<\/strong> of cases are in adults, 9% in juveniles.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758865392971\"><strong class=\"schema-faq-question\"><strong>What treatments are currently used for dermatomyositis?<\/strong><\/strong> <p class=\"schema-faq-answer\">There is no cure, but treatment aims to reduce inflammation, skin complications, and muscle weakness. First-line treatments include systemic glucocorticoids with or without immunosuppressants. Other therapies used are antimalarials, antibiotics, topical steroids or calcineurin inhibitors, and for resistant cases, agents like rituximab, mycophenolate mofetil, IVIG, calcineurin inhibitors, or cyclophosphamide.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758865393785\"><strong class=\"schema-faq-question\"><strong>What promising therapies are in development?<\/strong><\/strong> <p class=\"schema-faq-answer\">Several promising therapies are in development for dermatomyositis, with many advancing into late-stage clinical trials. Key candidates include <strong>Brepocitinib<\/strong>, a TYK2\/JAK1 inhibitor showing potential in modulating immune pathways, and <strong>PF-06823859<\/strong>, an IFN\u03b21 blocker targeting inflammatory processes. <strong>KZR-616 (zetomipzomib)<\/strong> is another notable agent, designed to regulate immune responses by selectively modulating protein degradation. In addition, <strong>Efgartigimod combined with PH20 hyaluronidase<\/strong> is being evaluated to enhance antibody clearance, while <strong>HIZENTRA<\/strong>, <strong>Daxdilimab (HZN-7734)<\/strong>, and <strong>PN-101<\/strong> are emerging as potential options to expand treatment choices for patients. These investigational therapies highlight the growing focus on targeted and innovative approaches beyond conventional immunosuppressants.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758865394329\"><strong class=\"schema-faq-question\"><strong>What are the main challenges or barriers in treating dermatomyositis effectively?<\/strong><\/strong> <p class=\"schema-faq-answer\">Key obstacles include disease heterogeneity (adult vs juvenile forms have different features), diagnostic delays, lack of standardized outcome measures, and limited effective therapies. Also, animal models do not fully mimic human disease, which complicates preclinical research. There is also the issue of side effects from existing treatments (e.g. steroids).\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758865433630\"><strong class=\"schema-faq-question\"><strong>How is the market for dermatomyositis treatments evolving?<\/strong><\/strong> <p class=\"schema-faq-answer\">The market size in 2023 was about <strong>USD 187 million<\/strong> in the 7 major markets, with immunoglobulins (e.g. IVIG) being the largest segment (~USD 119 million). The market is projected to grow at a CAGR of ~16.8%, driven by rising awareness, better diagnostics, and the arrival of new therapies.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dermatomyositis, characterized by muscle weakness and skin symptoms, is a condition linked to increased morbidity and mortality. It markedly affects the quality of life for individuals afflicted, as well as the well-being of their families. According to DelveInsight\u2019s estimates, in 2023, there were nearly 72K diagnosed prevalent cases of dermatomyositis in the seven major markets [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":25797,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[21096,21496,21097,21498,21497,21495],"industry":[17225],"therapeutic_areas":[17237],"class_list":["post-25796","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-dermatomyositis","tag-dermatomyositis-drugs","tag-dermatomyositis-market","tag-dermatomyositis-patients","tag-dermatomyositis-symptoms","tag-dermatomyositis-treatment","industry-pharmaceutical","therapeutic_areas-dermatology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Navigating the Challenges in Dermatomyositis Treatment<\/title>\n<meta name=\"description\" content=\"In the last two decades, many advancement yielded new insights, paving way for promising therapeutic approaches for dermatomyositis treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Navigating the Challenges in Dermatomyositis Treatment\" \/>\n<meta property=\"og:description\" content=\"In the last two decades, many advancement yielded new insights, paving way for promising therapeutic approaches for dermatomyositis treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-27T14:12:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-26T05:45:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152206\/dermatomyositis-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Navigating the Challenges in Dermatomyositis Treatment","description":"In the last two decades, many advancement yielded new insights, paving way for promising therapeutic approaches for dermatomyositis treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook","og_locale":"en_US","og_type":"article","og_title":"Navigating the Challenges in Dermatomyositis Treatment","og_description":"In the last two decades, many advancement yielded new insights, paving way for promising therapeutic approaches for dermatomyositis treatment.","og_url":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-05-27T14:12:36+00:00","article_modified_time":"2025-09-26T05:45:20+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152206\/dermatomyositis-treatment.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook","url":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook","name":"Navigating the Challenges in Dermatomyositis Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152206\/dermatomyositis-treatment.png","datePublished":"2025-05-27T14:12:36+00:00","dateModified":"2025-09-26T05:45:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"In the last two decades, many advancement yielded new insights, paving way for promising therapeutic approaches for dermatomyositis treatment.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865387381"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865392971"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865393785"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865394329"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865433630"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152206\/dermatomyositis-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152206\/dermatomyositis-treatment.png","width":772,"height":482,"caption":"dermatomyositis-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865387381","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865387381","name":"What is dermatomyositis and how common is it?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Dermatomyositis is a rare autoimmune disease characterized by inflammation of muscle (myositis) and skin (dermatitis). In 2023, there were approximately <strong>72,000 diagnosed cases<\/strong> in the seven major markets (US, Germany, France, Italy, Spain, UK, Japan). About <strong>91%<\/strong> of cases are in adults, 9% in juveniles.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865392971","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865392971","name":"What treatments are currently used for dermatomyositis?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"There is no cure, but treatment aims to reduce inflammation, skin complications, and muscle weakness. First-line treatments include systemic glucocorticoids with or without immunosuppressants. Other therapies used are antimalarials, antibiotics, topical steroids or calcineurin inhibitors, and for resistant cases, agents like rituximab, mycophenolate mofetil, IVIG, calcineurin inhibitors, or cyclophosphamide.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865393785","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865393785","name":"What promising therapies are in development?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Several promising therapies are in development for dermatomyositis, with many advancing into late-stage clinical trials. Key candidates include <strong>Brepocitinib<\/strong>, a TYK2\/JAK1 inhibitor showing potential in modulating immune pathways, and <strong>PF-06823859<\/strong>, an IFN\u03b21 blocker targeting inflammatory processes. <strong>KZR-616 (zetomipzomib)<\/strong> is another notable agent, designed to regulate immune responses by selectively modulating protein degradation. In addition, <strong>Efgartigimod combined with PH20 hyaluronidase<\/strong> is being evaluated to enhance antibody clearance, while <strong>HIZENTRA<\/strong>, <strong>Daxdilimab (HZN-7734)<\/strong>, and <strong>PN-101<\/strong> are emerging as potential options to expand treatment choices for patients. These investigational therapies highlight the growing focus on targeted and innovative approaches beyond conventional immunosuppressants.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865394329","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865394329","name":"What are the main challenges or barriers in treating dermatomyositis effectively?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key obstacles include disease heterogeneity (adult vs juvenile forms have different features), diagnostic delays, lack of standardized outcome measures, and limited effective therapies. Also, animal models do not fully mimic human disease, which complicates preclinical research. There is also the issue of side effects from existing treatments (e.g. steroids).\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865433630","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/dermatomyositis-treatment-outlook#faq-question-1758865433630","name":"How is the market for dermatomyositis treatments evolving?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The market size in 2023 was about <strong>USD 187 million<\/strong> in the 7 major markets, with immunoglobulins (e.g. IVIG) being the largest segment (~USD 119 million). The market is projected to grow at a CAGR of ~16.8%, driven by rising awareness, better diagnostics, and the arrival of new therapies.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/04152206\/dermatomyositis-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dermatomyositis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dermatomyositis Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dermatomyositis Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dermatomyositis Patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dermatomyositis Symptoms<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dermatomyositis Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Dermatomyositis<\/span>","<span class=\"advgb-post-tax-term\">Dermatomyositis Drugs<\/span>","<span class=\"advgb-post-tax-term\">Dermatomyositis Market<\/span>","<span class=\"advgb-post-tax-term\">Dermatomyositis Patients<\/span>","<span class=\"advgb-post-tax-term\">Dermatomyositis Symptoms<\/span>","<span class=\"advgb-post-tax-term\">Dermatomyositis Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 months ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on May 27, 2025","modified":"Updated on Sep 26, 2025"},"absolute_dates_time":{"created":"Posted on May 27, 2025 7:42 pm","modified":"Updated on Sep 26, 2025 11:15 am"},"featured_img_caption":"dermatomyositis-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25796"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25796\/revisions"}],"predecessor-version":[{"id":33487,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25796\/revisions\/33487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25797"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25796"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25796"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}